

Stop the Bleeding: Updates in Anticoagulation Reversal

ACPE Activity Number: 0204-9999-16-408-L01-P

Activity Date: 9/13/2016

Activity Time: 12:00 p.m. - 1:00 p.m. ET

Activity Type: *Knowledge-based*

CE Credits: 1.0 hour (0.1 CEU) CPE

Activity Fee: *Subscription-based service*

Accreditation for Pharmacists



The American Society of Health-System Pharmacists and UNC Eshelman School of Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

This continuing pharmacy education activity is designed for pharmacists.

Activity Overview

Evaluation and treatment of the anticoagulation reversal requires extensive knowledge of drug characteristics, pharmacokinetics, toxicities, and mechanisms for reversal. The existence of formal treatment guidelines and published research and trials to address emergency anticoagulation reversal is exceptionally sparse. There is a lack of primary literature in regards to evaluation, comparative efficacy, and treatment of emergency anticoagulation reversal to assist healthcare providers who may be involved in the care of these patients. Development and approval of new, targeted reversal therapies is happening at a rapid pace, ahead of literature to guide therapeutic decisions.

This activity will review the anticoagulant therapy drug classes and the agents used for their reversal, discuss steps to evaluate and triage anticoagulation reversal in patients, and review principles of clinical management and therapy for anticoagulation reversal and corresponding treatment and monitoring algorithms for patients.

Learning Objectives

After participating in this CPE activity, participants should be able to:

- Review classes of anticoagulants and associated anticoagulation reversal agents and their mechanism of action.
- Explain the systematic steps utilized in proper evaluation and triage of the anticoagulation reversal patient.
- State the general principles of clinical management and therapy for anticoagulation reversal patients and corresponding treatment and monitoring algorithms.

Activity Announcement

- Apply evaluation and treatment concepts to anticoagulation reversal patient cases.

Faculty Information

Leah M. Hatfield, Pharm.D., BCPS
Lead Clinical Pharmacist Specialist, Emergency Medicine
UNC Hospitals
Assistant Professor of Clinical Education- UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Dr. Leah Hatfield earned her Doctor of Pharmacy from Mercer University College of Pharmacy and Health Sciences in 2004. She started her career as an active duty pharmacist in the United States Navy, stationed at Naval Medical Center San Diego. While there, she completed a pharmacy practice residency with a focus in adult and pediatric critical care and became a Board Certified Pharmacotherapy Specialist. She also practiced as a clinical specialist in adult and pediatric intensive care and served in multiple humanitarian medical missions about the USS Nimitz, USS Reagan, and USNS Mercy. She relocated to Atlanta in 2007, and continued her practice as an Emergency Medicine Clinical Specialist at both Children's Healthcare of Atlanta and Grady Health System. She held faculty appointments at both Mercer University College of Pharmacy and Health Sciences and Emory University School of Medicine. Dr. Hatfield joined the staff at UNC in 2012, and is currently the Lead Clinical Pharmacist Specialist in Emergency Medicine there, and she holds a faculty appointment as an Assistant Professor of Clinical Education at UNC Eshelman School of Pharmacy. She is a certified ACLS and PALS instructor. Her research interests include trauma care and resuscitation, traumatic brain injury, emergent anticoagulation reversal, and toxicology.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

In keeping with this requirement, ASHP asks that all faculty, advisory board members, planning committee members, content development consultants, and staff complete a disclosure form for each program in which they are involved. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Faculty, planner, ASHP Staff and consultants report no relevant financial relationships pertinent to this activity, except:

Activity Announcement

- Leah M. Hatfield, Pharm.D., BCPS, declares that she serves as a scientific expert consultant for Portola Pharmaceuticals.

Methods and CE Requirements

This activity consists of a 1-hour webinar.

Participants must participate in the entire activity and complete the online evaluation to earn continuing pharmacy education credit.

Follow the prompts to claim credit immediately or within 60 days after the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.